Oxidized LDL and Risk of Coronary Heart Disease
Article Sidebar
Main Article Content
Abstract
Oxidized LDL cholesterol (ox-LDL) is considered to be a key factor of initiating and accelerating coronary heart disease CHD and diabetes Mellitus DM , is associated with several mechanisms one of them Oxidative stress. The aim of this study was to find the association between ox- LDL ,HDL-C , TG , LDL-C and arylesterase , with CHD risk in different age groups in males and females , the difference in these risk factors can explain the sex difference and how much the changes in the risk factors levels in CHD and CHD with DM patients between age groups.
Methods: determination biochemical parameters of serum blood of ox-LDL , TG , TC , HDL-c , LDL-c , S. Glucose and arylesterase activity were measured in cases male and females were carried CHD and CHD with DM .The cases divided in different the age groups (40-49) , (50-59) and (60-69) years and compered the result with control groups .
Results: mean Value of ox-LDL and oxidation ratio of LDL show significantly higher at (p<0.05) in CHD and (p<0.001) in CHD with DM patient for females in the age group (40-49) years but in the males show the results significant decrease and different significant in others groups ,beside to effect Sex and age some the studied biochemistry parameters levels and signification decrease in HDL-C and arylesterase levels as antioxidant enzymes in females and male patient selected compared with control groups.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Tsimikas S. (2006) . Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease .Am J. Cordial , 98:9P-17P.
2.Hansson GK.(2005). Inflammation, atherosclerosis, and coronary artery disease. N Engl J. Med, 352: 1685-95.
3. Navab M. Ananthramaiah GM. Reddy ST. Van Lenten BJ. Ansell BJ. Fonarow GC. Et al. (2004) .The oxidation hypothesis of atherogenesis : the role of oxidized phospholipids and HDL. J. Lipid Res, 45:993-1007.
4. Glass CK. Witztum JL. (2001) . Atherosclerosis . The road ahead . Cell ,104:503-16.
5. Suglyama S. Okada Y. Sukhova GK. Virmani R. Heinecke JW. Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulation factor in human atherosclerosis and implication in acute coronary syndromes . Am J. Pathol, 158:879-91.
6. Koenig W. Karakas M. Zierer A. Herder C. Baumert J. Meisinger C. and Thorand B. (2011) . Oxidized LDL and the risk of coronary heart disease : Results from the MONICA/KORA Augsburg study . Clinical Chemistry ,57;8:1196-1200.
7. Lakshmy R. Ahmed D. Abraham R. Sharma M. Vemparala K. Das S. Reddy K. and Prabhakaran D. (2010). Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infraction & association with oxidized low density lipoprotein . Indian J. Med. Res.,131,pp:522-529.
8. Mackness MI. Mackness B. Durrington PN. Fogelman AM. Berliner J. Lusis AJ. Et al .(1998) .Paraoxonase and coronary heart disease . Curr Opin Lipidol, 9:319-24.
9. Whatson AD. Navab M. Hama SY. Sevanian A. Prescott SM. Stafforini DM. et al. (1995) .Effect of platelet activating factor acetyl hydrolase on the formation and action of minimally oxidized low density lipoprotein . J. Clin. Invest . 95:774-82.
10. Klimov AN. Nikiforova AA. Pleskove VM. Kuzmin AA. Kaleshnikova NN. Antipova TO. (1989).The protective action of high density lipoproteins, their subfraction and lecithin cholesterol acylhydrolase in the peroxide modification of low density lipoprotein. Biokkimiya , 54:118-23.
11. Holvoet P. Harris T. Tracy R. Verhamme P. Newman A. Rubin S. Simonsick E. Colbert L. Kritchevsky S. (2003) .Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly. Arterioscler Thromb Vasc. Biol. , 23:1444-1448.
12. Fan J. Watanabe T. (2003a) . Transgenic rabbits as therapeutic protein bioreactors and human disease models . Pharmacol Ther., 99:261-282.
13. Laboz C. Mostaza J.M.(2007). Atherosclerosis as a systemic disease .Rev. Esp. Cardiol, 60:184-195.
14. Wiersma J. Meuwese M. and Van Meret J.(2008). Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase , Med Sci. Monit. , 14:406-4.
15. Singh U. and Jialal I. (2006). Oxidative stress and atherosclerosis. Pathophysiology,13:129-142.
16. Al-Hadidy A. Al-Kattan M. Jankeer M. (2014) . Relationship between pomegranate (Punica granatum) and paraoxonase enzyme to prevent the
development of atherosclerosis in male white new Zealand rabbits . International Journal of Enhanced Research in Science Technology & Engineering .,Vol.3,Issue 5. pp:242-250 .
17. Halliwell B and Gutteridge J. (1999) . Free radicals in biology and medicine , The 3rd Edition by:Oxford University Press, Oxford.
18. Garg S. Suneja M. (2015). Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic stutus in early stages of type-2 diabetes mellitus. Indian J. Med. Res. ,pp:107-114.
19. Allwsh T. Jasim R. (2008), Study of arylesterase and it’s relationship with some clinical variables in atherosclerotic patients in mosul (Part I) , Al-Rafidain Journal of science ,Vol.19 ,No.2 , pp:143-157.
20. Mac Phee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ , Leach CA, et al., (1999) . Lipoprotein –associated phosoholipase A2, platelet-activating factor acetylhydrolase, generates, two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J, 338: 479-87
21. Frantz F. Menezes H.S., Lange K.C. Abegg M.P., Correa C.A., Zangalli L., Viera J.L., Zettler C.G., (2012). The effect of maternal hypercholesterolemia on the placenta and fetal arteries in rabbits . Acta Cirurgica Brasileira ,27(1):7-12.
22. Alassane D., Fatou C., Fatou G.T..,Fatou D., Oumar T.F.A., Ndene S.G.,Philomene L.S., Diop S.N., and Meissa T., (2014), Serum lipids and oxidized low density lipoprotein levels in sickle cell disease: Assessment and pathobiological significance, African Journal of Biochemistry Research, Vol. 8(2); pp:39-42.
23. Nakhjavani M.,Esteghamat A., Asgarani F., et al .(2009), Association of oxidized low-density lipoprotein and transforming growth factorbeta in type 2 diabetic patients: a cross-sectional study , Transl. Res.,153(2):86-90.
24. Huang H., Mai W., Liu D., Dong Y.,(2016), Oxidised low-density lipoprotein cholesterol and their ratio in the diagnosis and treatment of coronary heart disease, Heart ,Vol.97:pp:A135-A136.
25. Jousilahti P.,Vartiainen E.,Tuomilehto J.,Puska P.,(1999). Sex ,age cardiovascular risk factor , and coronary heart disease, A prospective follow-up study of 14 786 middle –aged men and women in finland . American Heart Association ,99:1165-1172.
26. Matthews KA., Meilahn E., Kuller LH., Kelsey SF., Caggiula AW., Wing RR., (1989) . Menopause and risk factors for coronary heart disease . N. Engl J. Med., 321:641-646.
27. Bonithon-Kopp C., Scarabin P-Y., Darne B., Malmejak A., Guise I., (1990), Menopause– related changes in lipoprotein and some other cardiovascular risk factors , Int. J. Epidemiol.,19:42-48.
28. Kiranmayi P.V., Vivekanand N., Pandit V.L. (2014) . The study of lipid profile and oxidized-LDL in type 2 diabetes mellitus, Sch. J. App. Med. Sci., 2(3D):1119-1122.
29. Poulsen MK.,Henriksen JE., Dahl J., Johansen A., Gerke O, Vach W, Haghfelt T., Hoilund-Carlsen PF, Beck-Nielsen H., Moller JE., (2010), Left ventricular diastolic function in type 2 diabetes mellitus prevalence and association with myocardial and vascular disease . Circ . Cardiovasc Imaging ,3:24-31.
30. Salehzadeh F., Rune A., Osler M., and Al-Hhalili L., (2011), Testosterone or 17ẞ -estradiol exposure reveals sex-specific effects and lipid metabolism in human myotubes. Journal of Endocrinology, 210; 219-229.
31. Kota S.K., Meher L.K., Kota S.K., Jammula S., Krishna S.V.S., and Modi K.D., (2013). Implication of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian J. Endocrinol Metab . 17(3):402-412.
32. Kumar D. and Rizvi S.I.,( 2014) , Age–dependent paraoxonase 1 (PON1) activity and LDL oxidation in wistar rats during their entire lifespan.The Scientific World Journal,Vol.2014,pp:1-6.
33. Huang H., Ma R. Liu D. Liu C. Ma Y. Mai W., and Dong Y., (2012). Oxidized low density lipoprotein cholesterol and the ratio in the diagnosis and evaluation of therapeutic effect in patients with coronary artery disease, Disease Marker ,33:295-302.
34. Huang Y., Hu Y, Mai W., Cai X., Song Y, et al (2011), Plasma oxidized low-density lipoprotein is an independent risk factor in young patients with coronary artery disease, Dis Markers 31(5):295-301.
35. Essam Eldin MN, Abdullah A, Adel MA, et al. (2014), Oxidized low density lipoprotein and total antioxidant capacity in type 2 diabetic and impaired glucose tolerance Saudi men, Diabetology & Metabolic Syndrome ,6(94):1-10.
36. Baigent C, Blackwell J, Holland LE, et al (2010) , Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170000 participants in 26 randomised trails, Cholesterol Treatment Trialists (CTT) Collaboration, lancet, 376:1670-1681.
37. Pasterkamp G, van Lammeren GW, (2010), Pleiotropic effects of statins in atherosclerotic disease , Expert Rev. Cardiovasc Ther. ,8(9):1235-1237.
38. Longo DL, Dennis L., Kasper F, Hause SL, Jameson JL, Loscalzo J, (2008), Harrison’s principles of internal medicine, 18th edition, New York, McGraw Hill Company ;Vol.1.
39. Faulin TES, Garcia MCC, Abdalla DSP, (2009), Recent advances on detection of modified forms of low-density lipoprotein, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 3:28-34.
40. Sertic J, Skoric B, Lovric J, Bozina T, Reiner Z, (2010), Does Lp-PLA2 determination help predict atherosclerosis and cardio-cerebrovascular disease ? Acta Med Croatica ,64(4):237-45.
41. Van Dijk TH, Laskewitz AJ, Grefhorst A, Boer TS, Bloks VW, Kuipers F, Groen AK, Reijngoud DJ. (2013), A novel approach to moitor glucose
metabolism using stable isotopically labeled glucose in longitudinal studies in mice. Lab. Anim.,47(2):79-88.
42 Heriansyah T, Bambang BS, Anwar S, Djanggan S, and Aulanni’am A, (2016), The effect of darapladip on lipid profile, insulin, ox-LDL serum level and PVAT thickness at atherogenesis development in DM type2 rats model, International Journal of Pharm Tech Research, Vol.9,No.2:pp.01-08.
43. Gobal FA., and Metha FL., (2010) , Management of dyslipidemia in the elderly population , Ther Adv Cardiovasc Dis , 4:375-383.
44. Jamuna Rani A, Mythili SV, Nagarajan S,(2014) , Study on paraoxonase1 in type 2 diabetes mellitus , Indian J. Physiol Pharmacol ; 58:13-16.
45. Kola SK. Meher LK, Kola SK, Jammula S, Krishna SV, Modi KD, (2013), Implication of serum paraoxonase activity in obesity diabetes mellitus and dyslipidemia, Indian J. Endocrinol Metab,2013:402-412.
46. Namitha D, Nusrath A, Rajeshwari A, Rani NA, (2015), Serum paraoxonase levels in type 2 diabetes mellitus patients: A case – control study , Journal of Medical Sciences and Health , Vol.01,Issue 02;pp:14-18.